Of note, ALL-SIL, MOLT-4 and RPMI-8402 cell lines showed a JAK1/2-STAT6 activation profile close to patients with worse prognosis as well as high levels of JAK2 Y1007-1008 compared to good prognosis patients and to the other leukemia cell lines. The gene discussed is JAK2; the disease is leukemia.